GLP-1 Muscle Loss: How Much Is Real, and What Helps

If you have started semaglutide or tirzepatide, or you are thinking about it, you have probably run into a scary headline about GLP-1 muscle loss. Some versions claim these drugs strip 40% of your weight loss straight out of your muscle. Others insist the concern is manufactured. Neither extreme survives contact with the actual trial data.

Here is what the evidence supports: yes, you lose lean tissue on a GLP-1. No, most of it is not muscle. And the amount you lose is largely within your control.

Below is a look at what the DXA and MRI substudies found, why the number people quote is misleading, who actually needs to worry, and the specific protein and training targets that clinical guidelines now recommend.

Quick Summary

• In the STEP 1 semaglutide substudy, total fat mass dropped 19.3% while total lean body mass dropped 9.7% over 68 weeks. Lean mass as a share of total body weight went up, not down.

• In the SURMOUNT-1 tirzepatide substudy, roughly 75% of weight lost was fat and 25% was lean mass. The placebo group showed the same 75/25 split.

• Lean mass is not muscle. It includes organs, bone mineral, body water, and the non-fat portion of fat tissue itself. Skeletal muscle is only about half of it.

• MRI data from SURPASS-3 found that thigh muscle volume loss with tirzepatide tracked closely with what you would predict from the weight loss alone, while muscle fat infiltration improved more than expected.

• Measured strength has generally held steady in short and medium trials, even when muscle size dropped. Older adults are the group where caution is most warranted.

• Expert consensus is direct on the fix: at least three strength training sessions per week plus adequate protein. Protein alone is not enough.

• Protein targets during active weight loss run roughly 1.2 to 1.6 g/kg per day, or a simpler absolute target of 80 to 120 g per day.

• Bone matters too. In a randomized trial, GLP-1 therapy alone reduced hip and spine bone density while adding exercise preserved it.

What Does "GLP-1 Muscle Loss" Actually Mean?

GLP-1 muscle loss refers to the reduction in lean body mass that accompanies weight loss on drugs like semaglutide and tirzepatide. In the major trials, lean mass accounted for roughly 25% to 40% of total weight lost, depending on the trial and the measurement method. But "lean mass" on a body composition scan is not a synonym for muscle. It bundles skeletal muscle together with organ tissue, bone, connective tissue, glycogen, and body water, so the figures overstate how much actual muscle disappears.

Why lean mass is not muscle

This distinction is not a technicality. It changes the math.

DXA and bioelectrical impedance both estimate fat-free mass, which includes muscle plus organs, bone, fluids, and the water and connective tissue held inside fat tissue itself. When you lose 20 kg of body fat, you mechanically lose some of the non-fat scaffolding that came with it, and the scan reads that as lean mass loss.

Organ shrinkage contributes as well. In preclinical work published in Cell Reports Medicine in March 2026, researchers found that among lean tissues in obese mice treated with GLP-1 medicines, the loss of liver mass exceeded the change in muscle mass. A fatty liver returning toward normal size registers on a scan as lean tissue loss, and that is a good outcome, not a bad one.

Body water shifts add more noise. Rapid weight loss depletes glycogen, and each gram of glycogen holds roughly three grams of water with it.

One expert advisory summarizing the STEP 1 body composition data laid out the arithmetic: of roughly 13.6 kg lost, about 8.3 kg was fat mass and about 5.3 kg was lean body mass. Because skeletal muscle is about half of lean body mass, that works out to roughly 20% of total weight loss being actual muscle.

How Much Muscle Do You Actually Lose on a GLP-1?

Here is what the dedicated body composition substudies reported.

That last row is the one most articles leave out. In SURMOUNT-1, the 75/25 fat-to-lean split was the same in the placebo group as in the tirzepatide group, and it held across sex, across age brackets including participants 65 and older, and across every tier of weight loss. The drug changed how much weight came off. It did not change the composition of what came off.

What semaglutide did to body composition

In STEP 1, semaglutide 2.4 mg reduced total fat mass by 19.3% and visceral fat by 27.4% over 68 weeks. Lean body mass fell 9.7% in absolute terms. But because fat fell so much faster, lean mass as a proportion of total body weight rose by 3.0 percentage points. Participants finished the trial with a higher percentage of their body as lean tissue than when they started.

A 2026 meta-analysis in the International Journal of Obesity pooled seven randomized trials covering 821 patients and found the same pattern: absolute lean mass dropped 1.74 kg on average, while lean mass as a proportion of total weight increased by 1.81%. The authors concluded that lean mass loss should not be treated as a reason to avoid these drugs, but that treatment should be paired with nutrition and exercise intervention.

What MRI shows that DXA cannot

The SURPASS-3 MRI substudy is the most informative study on this question, because MRI can measure actual thigh muscle volume and the amount of fat infiltrating the muscle. DXA cannot separate those.

Over 52 weeks in 246 people with type 2 diabetes, tirzepatide produced about 10% weight loss along with a 0.64 L reduction in thigh muscle volume and a 0.36 percentage point reduction in muscle fat infiltration.

The researchers then compared those changes against longitudinal MRI data from 2,942 UK Biobank participants to answer the key question: is this more muscle loss than you would expect from that much weight loss?

The answer was no. Observed muscle volume loss did not differ significantly from the population-based estimate. Meanwhile, the improvement in muscle fat infiltration was significantly larger than predicted, and roughly two to four times greater than the average worsening seen with a single year of aging. Muscle quality improved beyond what the weight loss alone would explain.

For contrast, the comparison group in that trial received insulin degludec, gained 3.3% body weight, and gained a small amount of muscle volume. Gaining weight adds muscle. Losing weight costs some. That is physiology, not a drug side effect.

Is GLP-1 Muscle Loss Worse Than Losing Weight Any Other Way?

On current evidence, no. Lean mass reductions with GLP-1 medications look comparable to what has been documented after bariatric surgery and with very low calorie diets that produce similar weight loss.

The reason GLP-1s attract more attention is simple: they work better. A 21% weight loss with 25% of it as lean mass removes far more absolute lean tissue than a 6% weight loss with the same 25% split. The percentage is unremarkable. The absolute number is large, because the weight loss is large.

There is one genuine open question. In the Cell Reports Medicine work, GLP-1 treatment produced a different muscle protein signature than calorie restriction did, even when weight loss was matched. What that means over years is not yet known. It is worth watching, and it is not currently a reason for alarm.

Does Losing Lean Mass on a GLP-1 Make You Weaker?

Mostly the measured answer has been no, with an important caveat for older adults.

In the proof-of-concept clinical arm of the 2026 Cell Reports Medicine study, thigh muscle cross-sectional area shrank significantly, yet maximum voluntary knee extension force and handgrip strength did not change. In the SEMALEAN study, which followed 106 patients on semaglutide 2.4 mg for a year, handgrip strength improved by 4.5 kg and the prevalence of sarcopenic obesity fell from 49% at baseline to 33% at 12 months.

Part of this is that carrying less body weight makes the same absolute strength go further. Part of it is that clearing fat out of muscle improves force production per unit of tissue.

The caveat is real, though. A 2026 review in the British Journal of Pharmacology noted that while short and medium trials in middle-aged adults show preserved strength, emerging longitudinal and observational data in older adults point to possible accelerated grip strength decline. That population needs monitoring, not reassurance.

Who Is Most at Risk of Muscle Loss on GLP-1 Medications?

• Adults over 60, who start with less muscle and less capacity to rebuild it

• Anyone already sedentary who does no resistance training before or during treatment

• People losing weight very fast, since rate of loss drives lean tissue loss independently

• Anyone with pre-existing sarcopenia or low muscle mass, including many people with type 2 diabetes

• People with significant nausea or food aversion who cannot hit protein targets

• Men, per modeling data suggesting muscle accounts for 20% to 25% of weight lost in males versus 10% to 15% in females without strength training

• Anyone cycling on and off the medication, since repeated loss and regain tends to trade muscle for fat over time

That last point deserves emphasis. Real-world discontinuation runs about 33% to 50% at one year and roughly 15% remain on treatment at two years, and up to two-thirds of lost weight comes back within a year of stopping. Regained weight comes back disproportionately as fat. Stopping and restarting without a training habit is probably the single biggest muscle risk in this whole picture.

How to Protect Muscle on a GLP-1: Step by Step

1. Get a baseline body composition measurement before you start. DXA is the gold standard. Bioelectrical impedance is cheaper and easier to repeat. Without a baseline you are guessing.

2. Test your baseline function too. A sit-to-stand count, a timed stair climb, or a grip dynamometer reading gives you something objective to re-check. Strength matters more than the number on a scan.

3. Start resistance training before your first dose if you can. Three sessions per week is the guideline-recommended floor. Build the habit while your appetite is still normal.

4. Set a protein target and treat it as non-negotiable. Eat protein first at every meal, before anything else on the plate.

5. Add at least 150 minutes of moderate aerobic activity weekly. Aerobic work alone does less for lean mass than strength work, but it supports insulin sensitivity, vascular function, and cardiorespiratory fitness.

6. Do not let total calories crater. Intake below roughly 1,200 kcal for women or 1,800 kcal for men makes nutrient adequacy very difficult, and severe restriction accelerates lean tissue loss.

7. Titrate at a pace you can eat through. If nausea is keeping you from eating, staying at a lower dose longer is a reasonable conversation to have with your prescriber.

8. Rescan at 6 to 12 months. Compare lean mass and function, not just weight.

Protein Targets While Taking a GLP-1

GLP-1 medications reduce energy intake by 16% to 39%. Protein takes the hit first for most people, because protein-rich foods tend to be dense, slow to digest, and unappealing when you feel full.

Practical picks that deliver protein without much volume: Greek yogurt, cottage cheese, eggs, fish, lean poultry, and protein shakes when solid food is unappealing. Some people find nut butters easier to tolerate than a chicken breast during dose escalation.

One thing to be clear about: protein alone will not save your muscle. The joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society states plainly that increased protein intake is likely inadequate to preserve muscle mass without structured resistance training. Excess protein beyond what muscle can use gets converted to fat by the liver.

Resistance Training Is the Part You Cannot Skip

The strongest evidence for muscle preservation during GLP-1 weight loss is not a supplement or a protein powder. It is lifting.

The Copenhagen group ran the cleanest test. After an eight-week 800 calorie diet, 195 adults with obesity were randomized to exercise alone, liraglutide 3.0 mg alone, both combined, or placebo for 52 weeks. The combination cut body fat percentage by 3.9 percentage points, about double either intervention on its own. Only the combination improved HbA1c, insulin sensitivity, and cardiorespiratory fitness. The exercise group increased lean mass. The combination group preserved it despite substantial fat loss.

A published case series adds a real-world illustration. Three patients on semaglutide or tirzepatide who deliberately prioritized lean tissue with resistance training three to five days per week saw very different results from the trial averages. One lost 33.0% of body weight over 115 weeks with 91.2% of that loss coming from fat mass and only 8.7% from lean soft tissue. Two of the three actually increased lean soft tissue while losing weight. Case series cannot prove causation, but the contrast with the 25% trial average is hard to ignore.

Guideline-level recommendation: strength training at least three times weekly, plus at least 150 minutes of moderate aerobic exercise weekly. Retrospective GLP-1 data suggest that people hitting roughly 360 minutes of weekly structured activity with a strength emphasis do best for fat-free mass. Start where your fitness allows and progress.

What About Supplements?

This is where the marketing gets ahead of the evidence, so let me separate the two.

Protein supplements have the clearest case, not because protein powder is magic, but because hitting 80 to 120 grams per day with a suppressed appetite is genuinely hard. A shake is a delivery mechanism, not a treatment.

Creatine monohydrate has deep evidence for fat-free mass and strength alongside resistance training in the general population. A dedicated trial of creatine in people starting GLP-1 medications is currently underway, but has not reported. So the reasoning is extrapolation, not direct proof.

Vitamin D and calcium are worth attention because rapid weight loss affects bone, and because reduced food intake creates real deficiency risk. Iron, magnesium, zinc, B12, and vitamins A, E, and K are also on the watch list.

Anything marketed as preventing GLP-1 muscle loss should be treated with skepticism. No dietary supplement has been shown in a randomized trial to prevent lean mass loss in people on GLP-1 medications.

Where a product like BioPro+ fits, and where it does not

BioPro+ is our sublingual liquid formula built around elk antler velvet extract, which supplies bioactive proteins, peptides, and a full-spectrum amino acid profile, along with shilajit and functional botanicals including aloe vera, goji, and tribulus. The formulation is designed to support recovery, cellular energy production, and normal physiological function using naturally derived inputs rather than synthetic ones.

Two things make it a sensible fit for someone in a reduced-intake phase. First, it is a low-volume sublingual taken once in the morning, which matters when early satiety and food aversion make additional food or powder unappealing. Second, its ingredients are studied in relation to tissue maintenance, recovery, and metabolic function, which are exactly the systems under strain when total nutrient intake falls by a third.

Now the honest limits. BioPro+ does not supply protein in the gram quantities you need daily, so it is not a protein replacement. It has not been studied specifically in people taking GLP-1 medications. And it is not a substitute for resistance training, which remains the intervention with the best evidence by a wide margin. We position it as daily foundational support alongside those things, not instead of them.

These statements have not been evaluated by the Food and Drug Administration. BioPro+ is not intended to diagnose, treat, cure, or prevent any disease. Talk to your healthcare provider before combining any supplement with prescription medication.

Do Not Forget Bone

Muscle gets the headlines. Bone is arguably the more urgent concern, because you cannot feel bone loss until something breaks.

Weight loss that is both substantial, meaning 14% or more, and rapid, over three to four months, is associated with significant bone loss. Older adults and women lose more.

The Copenhagen trial measured this directly. Liraglutide alone reduced hip and spine bone mineral density despite the weight loss. Exercise alone fully preserved it. The combination of exercise plus the drug protected bone. Same weight loss, different skeletal outcome, and the variable was training.

If you are on a GLP-1 and postmenopausal, over 60, or already have low bone density, this belongs in a conversation with your clinician alongside calcium and vitamin D status.

What Is Coming: Drugs Built to Protect Muscle

The pharmaceutical industry took this concern seriously, and combination therapies are now in trials.

In the phase 2 BELIEVE trial published in Nature Medicine, 507 adults received bimagrumab, an activin type II receptor antibody, alone or combined with semaglutide over 72 weeks. High-dose bimagrumab plus semaglutide produced 22.1% weight loss versus 15.7% for semaglutide alone, with 92.8% of that loss coming from fat compared to 71.8% with semaglutide alone. Semaglutide 2.4 mg reduced lean mass by 7.4%. The combination limited that to 2.9%. Bimagrumab alone increased lean mass by 2.5%.

Regeneron's phase 2 COURAGE trial paired semaglutide with trevogrumab, an anti-myostatin antibody. At 26 weeks, 33% of semaglutide-induced weight loss was lean mass, and adding trevogrumab prevented roughly half of it.

Neither agent is FDA approved for this use, and neither is available. But the direction is clear: separating fat loss from lean loss appears to be pharmacologically achievable. For now, the tools you have are protein, resistance training, and pace.

The Bottom Line

GLP-1 muscle loss is real, frequently misquoted, and largely manageable.

The 25% to 40% lean mass figure is accurate as far as it goes, but lean mass includes water, organ tissue, bone, and the non-fat portion of fat tissue. Actual skeletal muscle is closer to 20% of weight lost. That proportion matches placebo groups, matches low-calorie diets, and matches bariatric surgery. MRI data suggest muscle volume declines about as much as the weight loss predicts, while muscle quality improves more than expected.

Your next steps:

• Get a baseline body composition scan and a baseline strength measure before you start, or as soon as possible if you have already started

• Commit to three resistance training sessions per week and treat that as part of the prescription

• Set a protein target of roughly 1.2 to 1.6 g/kg per day, or 80 to 120 grams, and eat protein first

• Add 150 minutes of moderate aerobic activity weekly

• Discuss bone density and vitamin D with your clinician if you are older or postmenopausal

• Rescan at 6 to 12 months and track function, not just weight

• Plan for how you will maintain training and protein if you ever come off the medication, because weight cycling is where muscle really goes

The people who lose the most muscle on these drugs are not the ones taking the highest dose. They are the ones who did nothing else.

Frequently Asked Questions

How much muscle do you lose on Ozempic or Wegovy?

In the STEP 1 body composition substudy, semaglutide 2.4 mg reduced total lean body mass by 9.7% over 68 weeks, which worked out to roughly 38% of total weight lost. Because skeletal muscle makes up about half of lean body mass, actual muscle loss was closer to 20% of weight lost. Lean mass as a proportion of total body weight increased by 3.0 percentage points, meaning body composition improved overall.

Does tirzepatide cause more muscle loss than semaglutide?

Not proportionally. In the SURMOUNT-1 substudy, about 75% of weight lost with tirzepatide was fat and 25% was lean mass, the same split seen in the placebo group. Because tirzepatide produces greater total weight loss, the absolute amount of lean tissue lost is larger, but the ratio is comparable. No head-to-head trial has directly compared the two drugs on muscle composition.

Can you build muscle while on a GLP-1?

Some people do. A published case series described patients on semaglutide or tirzepatide who resistance trained three to five days per week, and two of the three increased lean soft tissue while losing substantial body weight. It is harder in a calorie deficit, particularly for experienced lifters, but preserving and even adding lean tissue is achievable with consistent strength training and adequate protein.

How much protein should I eat on a GLP-1 to prevent muscle loss?

Current expert guidance suggests roughly 1.2 to 1.6 g per kg of body weight daily during active weight loss, or a simpler absolute target of 80 to 120 g per day. Do not drop below 0.4 to 0.5 g/kg/day. Eating protein first at each meal helps when appetite is reduced. Protein alone is not sufficient without structured resistance training.

Will I get weaker on a GLP-1?

Measured strength has generally held steady in short and medium-term trials. In one 2026 study, thigh muscle size decreased while maximum knee extension force and handgrip strength did not change. The SEMALEAN study found handgrip strength improved by 4.5 kg over 12 months. Older adults warrant closer monitoring, since some observational data suggest possible accelerated grip strength decline in that group. Tracking a functional measure like sit-to-stand or grip strength is more informative than tracking lean mass alone.

__________________________________

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting, stopping, or changing any medication or supplement.